- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
May 23rd, 2005
Jack Uldrich: In February, pSivida (Nasdaq: PSDV), an Australian-based company specializing in biomedical applications of nanotechnology, began trading on the Nasdaq as an American Depositary Receipt (ADR). In its first three months on Wall Street, it promptly fell from a high of $10 a share to just over $4.
Since that time, however, pSivida's stock has risen by more than 65%. It currently trades at around $7.
Will it continue to rise? I believe so, and I base that answer on three recent developments.
|Related News Press|
Molecular trick alters rules of attraction for non-magnetic metals August 5th, 2015
Global Carbon Nanotubes Industry 2015: Acute Market Reports August 4th, 2015
Nanometrics to Participate in the Citi 2015 Global Technology Conference August 26th, 2015
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010
An engineered surface unsticks sticky water droplets August 31st, 2015
New material science research may advance tech tools August 31st, 2015
Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015